CELEST, NCT02365649 / 2014-003240-12: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy |
|
|
| Completed | 2 | 220 | NA | Placebo, ABT-494, Upadacitinib | AbbVie | Crohn's Disease | 11/16 | 08/17 | | |
2021-006031-25: Investigation of a new treatment strategy for patients with the severe skin disease Lichen planus Untersuchung einer neuen Behandlungsstrategie für Patienten mit der schweren Hauterkrankung Lichen planus |
|
|
| Completed | 2 | 22 | Europe | Upadacitinib, Prolonged-release tablet | Charité - Universitätsmedizin Berlin, Abbvie | Patients with the chronic inflammatory skin disease Lichen planus will be treated with the JAK inhibitor upadacitinib. Patienten, die an der chronisch inflammatorischen Hauterkrankung Lichen planus leiden, werden mit dem JAK Inhibitor Upadacitinib behandelt., Patients with a skin disease (Lichen planus) will be treated with a substance that reduces the action of the immune system Patienten mit einer Hauterkrankung (Lichen planus) werden mit einer Substanz behandelt, die die Aktivität des Immunsystems reduziert., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
